Meeting
2020 ASCO Virtual Scientific Program
A phase II trial of PD-1 inhibition with INCMGA00012 in patients with previously treated unresectable or metastatic adenosquamous pancreatic cancer.
Authors
Christopher Jakubowski
Johns Hopkins Oncology, Baltimore, MD
Christopher Jakubowski , Elizabeth D Thompson , Hao Wang , Rosalind Walker , Elizabeth M. Jaffee , Nilofer Saba Azad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT04116073
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS4662)
DOI
10.1200/JCO.2020.38.15_suppl.TPS4662
Abstract #
TPS4662
Poster Bd #
270
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC).
First Author: Anup Kasi
Poster
2022 ASCO Annual Meeting
Toripalimab plus axitinib versus toripalimab or axitinib alone in patients with treatment-naive unresectable or metastatic mucosal melanoma: Interim results from a randomized, controlled, phase II trial.
First Author: Chuanliang Cui
Poster
2020 ASCO Virtual Scientific Program
EV-202: A phase II study of enfortumab vedotin in patients with select previously treated locally advanced or metastatic solid tumors.
First Author: Justine Yang Bruce